Who are Pemetrexed+carboplatin/Cisplatin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Pemetrexed+Cisplatin or Carboplatin, Pemetrexed + carboplatin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/pemetrexed-carboplatin-cisplatin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Pemetrexed+carboplatin/Cisplatin — Competitive Intelligence Brief

Pemetrexed+carboplatin/Cisplatin (Pemetrexed+carboplatin/Cisplatin) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antifolate antimetabolite + platinum-based chemotherapy combination. Area: Oncology.

phase 3 Antifolate antimetabolite + platinum-based chemotherapy combination Thymidylate synthase, dihydrofolate reductase, glycinamide ribonucleotide formyltransferase; DNA (platinum agents) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Pemetrexed+carboplatin/Cisplatin (Pemetrexed+carboplatin/Cisplatin) — Suzhou Puhe Pharmaceutical Technology Co., LTD. Pemetrexed inhibits multiple folate-dependent enzymes to disrupt DNA synthesis, while carboplatin or cisplatin cross-link DNA strands, together inducing cancer cell death.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Pemetrexed+carboplatin/Cisplatin TARGET	Pemetrexed+carboplatin/Cisplatin	Suzhou Puhe Pharmaceutical Technology Co., LTD	phase 3	Antifolate antimetabolite + platinum-based chemotherapy combination	Thymidylate synthase, dihydrofolate reductase, glycinamide ribonucleotide formyltransferase; DNA (platinum agents)
Pemetrexed+Cisplatin or Carboplatin	Pemetrexed+Cisplatin or Carboplatin	Sichuan Baili Pharmaceutical Co., Ltd.	phase 3	Antifolate antimetabolite + platinum-based chemotherapy combination	Thymidylate synthase, dihydrofolate reductase, glycinamide ribonucleotide formyltransferase; DNA (platinum agents)
Pemetrexed + carboplatin	Pemetrexed + carboplatin	AstraZeneca	phase 3	Antifolate antimetabolite + platinum-based chemotherapy combination	Thymidylate synthase, dihydrofolate reductase, glycinamide ribonucleotide formyltransferase (pemetrexed); DNA (carboplatin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antifolate antimetabolite + platinum-based chemotherapy combination class)

AstraZeneca · 1 drug in this class
Sichuan Baili Pharmaceutical Co., Ltd. · 1 drug in this class
Suzhou Puhe Pharmaceutical Technology Co., LTD · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Pemetrexed+carboplatin/Cisplatin — Competitive Intelligence Brief. https://druglandscape.com/ci/pemetrexed-carboplatin-cisplatin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab